(Q38845531)

6 September 2017

1 reference

title

Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes (English)

1 reference

6 September 2017

1 reference

3

Darren K McGuire

1 reference

6 September 2017

Eberhard Standl

1

1 reference

PubMed ID

27230644

6 September 2017

Oliver Schnell

series ordinal

2

1 reference

6 September 2017

1 May 2016

1 reference

6 September 2017

1 reference

6 September 2017

118

1 reference

6 September 2017

11

1 reference

6 September 2017

1830-1843

1 reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

6 September 2017

1 reference

12 December 2020

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

1 reference

12 December 2020

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

12 December 2020

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

12 December 2020

2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardi

1 reference

12 December 2020

Recognizing worsening chronic heart failure as an entity and an end point in clinical trials

1 reference

12 December 2020

Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium.

1 reference

12 December 2020

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

1 reference

12 December 2020

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

1 reference

12 December 2020

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

1 reference

12 December 2020

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

1 reference

12 December 2020

Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT.

1 reference

12 December 2020

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors

1 reference

12 December 2020

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

1 reference

12 December 2020

Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

1 reference

12 December 2020

Outpatient Worsening Heart Failure as a Target for Therapy: A Review.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

12 December 2020

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.

1 reference

12 December 2020

Effects of intensive glucose lowering in type 2 diabetes

1 reference

12 December 2020

Heart failure event definitions in drug trials in patients with type 2 diabetes

1 reference

12 December 2020

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

12 December 2020

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

1 reference

12 December 2020

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

12 December 2020

Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct

1 reference

12 December 2020

Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes

1 reference

12 December 2020

Trends in cardiovascular complications of diabetes

1 reference

12 December 2020

A randomized trial of therapies for type 2 diabetes and coronary artery disease

1 reference

12 December 2020

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

12 December 2020

The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

1 reference

12 December 2020

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

1 reference

12 December 2020

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

12 December 2020

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.

1 reference

12 December 2020

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes

1 reference

12 December 2020

Basal insulin and cardiovascular and other outcomes in dysglycemia

1 reference

12 December 2020

Novel Diabetes Drugs and the Cardiovascular Specialist

1 reference

12 December 2020

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

1 reference

12 December 2020

Results of a reevaluation of cardiovascular outcomes in the RECORD trial

1 reference

12 December 2020

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

12 December 2020

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

12 December 2020

Adjudication of serious heart failure in patients from PROactive

1 reference

12 December 2020

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

1 reference

12 December 2020

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial

1 reference

12 December 2020

Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits

1 reference

12 December 2020

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

1 reference

12 December 2020

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

1 reference

12 December 2020

Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?

1 reference

12 December 2020

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

12 December 2020

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

1 reference

12 December 2020

Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association

1 reference

12 December 2020

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

1 reference

12 December 2020

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.

1 reference

12 December 2020

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

1 reference

12 December 2020

Management of comorbid diabetes mellitus and worsening heart failure

1 reference

12 December 2020

The imperative of overcoming barriers to the conduct of large, simple trials

1 reference

12 December 2020

Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).

1 reference

12 December 2020

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

1 reference

12 December 2020

Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure

1 reference

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

12 December 2020

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD009008.PUB2

10.1161/CIRCRESAHA.116.306924

12 January 2024

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

27230644